Key facts
- Notable investors include Weinan Urban Investment Group, China Shaanxi Nuclear Equity Investment Management, Shaanxi Kekong Xietong Venture Capital, Shanxi Venture Capital Fund of Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for KQbio
- ·The full record, as it builds
Funding rounds
No funding rounds for KQbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KQbio
Developer of innovative biological vaccines designed for different diseases. The company focuses on the development and transformation of recombinant protein drugs, and the research, development, production and sales of human vaccines. Its products mainly cover the fields of tumor treatment, cardiovascular and cerebrovascular disease treatment, trauma repair and medical cosmetology.
- Sector
- Healthcare
- HQ
- Weinan, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
KQbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KQbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KQbio in its N-PORT filings yet. We sweep new filings monthly.